EUVIMEDEUVIMED entdecken
Open Access · CC BY-SA 4.0

Farmakoterapi Terkini pada Osteoporosis Pascamenopause

A Made Dea Rona Almas, Dicky Rizki Abadi Saputra

Jurnal Ilmiah Kedokteran dan Kesehatan · 11.07.2026 · 5 (3) · 472-484

DOI: 10.55606/klinik.v5i3.7627 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Jurnal Ilmiah Kedokteran dan Kesehatan, online erschienen am 11.07.2026. Verfasst von A Made Dea Rona Almas und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Postmenopausal osteoporosis is a systemic skeletal disorder characterized by reduced bone mass and microarchitectural deterioration of bone tissue, leading to increased fragility fracture risk. This literature review aimed to comprehensively compare two primary antiresorptive therapy classes bisphosphonates and denosumab across pharmacological mechanisms, clinical efficacy, safety profiles, and patient adherence. A systematic literature search was conducted using PubMed, Google Scholar, and SciSpace databases, restricted to peer-reviewed publications from 2019 to 2026, including randomized controlled trials, meta-analyses, and real-world evidence studies. Bisphosphonates act by inhibiting farnesyl pyrophosphate synthase (FPPS) in the mevalonate pathway, inducing osteoclast apoptosis, whereas denosumab inhibits RANKL, mimicking the physiological function of osteoprotegerin. Evidence demonstrates that denosumab produces superior bone mineral density (BMD) gains at the lumbar spine and total hip, alongside higher real-world treatment persistence rates. Within Indonesia's National Health Insurance (JKN/BPJS Kesehatan) system, bisphosphonates risedronate, alendronate, and zoledronic acid are listed in the National Formulary (Fornas KMK 2197/2023) and fully reimbursed, whereas denosumab (Prolia®, Xgeva®, and biosimilar Corora® approved by BPOM in April 2024) has not yet been included. Both drug classes carry rare but serious risks of medication-related osteonecrosis of the jaw (MRONJ) and atypical femoral fracture (AFF). It is concluded that bisphosphonates remain the effective and affordable first-line therapy within the BPJS framework, while denosumab represents a valuable alternative for patients with bisphosphonate intolerance or inadequate treatment response.

Zitieren

APA

Almas, A. M. D. R., & Saputra, D. R. A. (2026). Farmakoterapi Terkini pada Osteoporosis Pascamenopause. Jurnal Ilmiah Kedokteran dan Kesehatan, 5(3), 472-484. https://doi.org/10.55606/klinik.v5i3.7627

Vancouver

Almas AMDR, Saputra DRA. Farmakoterapi Terkini pada Osteoporosis Pascamenopause. Jurnal Ilmiah Kedokteran dan Kesehatan. 2026;5(3):472-484. doi:10.55606/klinik.v5i3.7627

BibTeX
@article{Almas2026,
  author = {Almas, A Made Dea Rona and Saputra, Dicky Rizki Abadi},
  title = {Farmakoterapi Terkini pada Osteoporosis Pascamenopause},
  journal = {Jurnal Ilmiah Kedokteran dan Kesehatan},
  year = {2026},
  volume = {5},
  number = {3},
  pages = {472--484},
  doi = {10.55606/klinik.v5i3.7627}
}
Kostenlos starten →